HR+/HER2- Metastatic Breast Cancer

The HR+/HER2- Metastatic Breast Cancer pipeline: 105 tracked drugs, 29 approved for this indication.

29 approved / phase 434 Phase 31 Phase 2/38 Phase 221 Phase 1/211 Phase 11 preclinical / unstaged

Compare the share prices of listed companies in HR+/HER2- Metastatic Breast Cancer →

Total attributable cost

$2.6B

$24,600/patient

Drug spend

Not yet sourced

How this is calculated ↗

Metastatic (stage IV), de novo and recurrent · US

The HR+/HER2- Metastatic Breast Cancer pipeline

Key trial results for every approved and late-stage drug: HR+/HER2- Metastatic Breast Cancer results by drug.

← all assets